Eli Lilly's Challenge to Rejoin the Trillion-Dollar Club
- Market Cap Fluctuation: Eli Lilly became the first healthcare company to surpass a $1 trillion market cap last year, but due to a poor start to 2026, its valuation has dropped to around $830 billion, posing a challenge for rejoining the trillion-dollar club.
- New Drug Approval Impact: The FDA approved Eli Lilly's weight loss drug Foundayo on April 1, which is easier to take than injectables and is expected to attract a broader patient base, potentially driving further company growth.
- Growth Potential: Eli Lilly has maintained a growth rate exceeding 40% in recent years due to the success of its GLP-1 drugs like Mounjaro and Zepbound, and sustaining this growth could make it an attractive option for growth investors.
- Price Expectations: Although the approval of Foundayo did not significantly boost the stock price, analysts have set a target price of $1,224, implying a potential upside of about 32%, with a 20% increase needed for Eli Lilly to return to a $1 trillion valuation.
Trade with 70% Backtested Accuracy
Analyst Views on LLY
About LLY
About the author
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
ELI LILLY IN FINAL DISCUSSIONS TO PURCHASE KELONIA THERAPEUTICS FOR OVER $2 BILLION - WSJ
- Eli Lilly's Acquisition Talks: Eli Lilly is engaged in advanced discussions to acquire Kelonia Therapeutics.
- Financial Implications: The potential acquisition is valued at over $2 billion.
ELI LILLY CLOSES IN ON AGREEMENT WITH CANCER BIOTECH FIRM - WSJ
Eli Lilly's Cancer Deal: Eli Lilly has reached a significant agreement in the cancer biotechnology sector, indicating a strategic move to enhance its portfolio in oncology treatments.
Impact on Biotechnology: This deal is expected to influence the biotechnology landscape, potentially leading to advancements in cancer therapies and improved patient outcomes.
Market Reactions: The announcement has garnered attention from investors and analysts, reflecting optimism about Eli Lilly's future growth and innovation in cancer treatment.
Future Developments: Further details on the specifics of the deal and its implications for Eli Lilly's research and development efforts are anticipated in upcoming reports.
Trump Administration Extends Medicare Coverage for Weight Loss Drugs
- Medicare Coverage Extension: The Trump administration has extended the short-term Medicare coverage for weight loss drugs until the end of 2027, responding to concerns from major health insurers about the long-term payment model, ensuring continued access to weight loss medications for patients.
- Direct Payment Mechanism: The new plan will have Medicare directly pay for weight loss medications instead of incorporating them into Medicare plans, alleviating the financial burden on health insurers and potentially increasing patient access and usage of these drugs, thus driving market growth.
- Data Collection Support: CMS indicated that this extension will facilitate data collection to support a more effective implementation of the long-term model, particularly in light of insufficient participation from health insurers, ensuring the feasibility and effectiveness of the policy.
- Insurer Participation Issues: CVS Health and UnitedHealth have expressed concerns regarding the long-term GLP-1 coverage model, with CVS explicitly opting out and UnitedHealth questioning its structure, highlighting the significance and complexity of insurer involvement in Medicare reforms.
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
ELI LILLY IN FINAL DISCUSSIONS TO PURCHASE KELONIA THERAPEUTICS FOR OVER $2 BILLION - WSJ
- Eli Lilly's Acquisition Talks: Eli Lilly is engaged in advanced discussions to acquire Kelonia Therapeutics.
- Financial Implications: The potential acquisition is valued at over $2 billion.
ELI LILLY CLOSES IN ON AGREEMENT WITH CANCER BIOTECH FIRM - WSJ
Eli Lilly's Cancer Deal: Eli Lilly has reached a significant agreement in the cancer biotechnology sector, indicating a strategic move to enhance its portfolio in oncology treatments.
Impact on Biotechnology: This deal is expected to influence the biotechnology landscape, potentially leading to advancements in cancer therapies and improved patient outcomes.
Market Reactions: The announcement has garnered attention from investors and analysts, reflecting optimism about Eli Lilly's future growth and innovation in cancer treatment.
Future Developments: Further details on the specifics of the deal and its implications for Eli Lilly's research and development efforts are anticipated in upcoming reports.
Trump Administration Extends Medicare Coverage for Weight Loss Drugs
- Medicare Coverage Extension: The Trump administration has extended the short-term Medicare coverage for weight loss drugs until the end of 2027, responding to concerns from major health insurers about the long-term payment model, ensuring continued access to weight loss medications for patients.
- Direct Payment Mechanism: The new plan will have Medicare directly pay for weight loss medications instead of incorporating them into Medicare plans, alleviating the financial burden on health insurers and potentially increasing patient access and usage of these drugs, thus driving market growth.
- Data Collection Support: CMS indicated that this extension will facilitate data collection to support a more effective implementation of the long-term model, particularly in light of insufficient participation from health insurers, ensuring the feasibility and effectiveness of the policy.
- Insurer Participation Issues: CVS Health and UnitedHealth have expressed concerns regarding the long-term GLP-1 coverage model, with CVS explicitly opting out and UnitedHealth questioning its structure, highlighting the significance and complexity of insurer involvement in Medicare reforms.
